Fetal hemoglobin for genetic correction of sickle cell disease
Methods and compositions disclosed herein generally relates to methods of determining minimum hematopoietic stem cell (HSC) chimerism and gene dosage for correction of a hematopoietic disease; in particular, in in vivo models. The invention also relates to modified lentiviral expression vectors for increasing a viral titer and various methods for increasing such titers as well as expression vectors capable of enhancing such titers. The invention also relates to CHS4 chromatin insulator-derived functional insulator sequences. The invention also relates to methods for genetic correction of diseases or reducing symptoms thereof, such as sickle cell anemia or β-thalassemia.
1. A mutated human gamma-globin gene, wherein the mutated human gamma-globin gene encodes a protein comprising SEQ ID NO: 1.
2. The mutated human gamma-globin gene, wherein the mutated human gamma-globin gene has a sequence identity of 70% or greater to SEQ ID NO: 2.
3. A method of using the mutated human gamma-globin gene of claim 1 to genetically correct sickle cell anemia or β-thalassemia or reduce symptoms thereof, the method comprising:
identifying a subject in need of treatment for sickle cell anemia or β-thalassemia;
transfecting autologous hematopoietic stem cells (HSCs) with a modified lentivirus comprising the mutated human gamma-globin gene of claim 1 ; and
transplanting the transfected HSCs into the subject.
4. The method of claim 3 , wherein the subject is a human subject.
5. The method of claim 3 , further comprising treating the subject with reduced intensity conditioning prior to transplantation.
6. The method of claim 3 , wherein the modified lentivirus further comprises
a heterologous polyA signal sequence downstream from a viral 3′ LTR sequence in a standard SIN lentiviral vector backbone; and
one or more USE sequences derived from an SV40 late polyA signal in a U3 deletion region of a standard SIN lentiviral vector backbone.
7. The method of claim 6 , wherein the modified lentivirus further comprises one or more flanking CHS4-derived reduced-length functional insulator sequences.
8. The method of claim 7 , wherein the modified lentivirus further comprises a beta-globin locus control region.
9. The method of claim 7 , wherein the modified lentivirus further comprises an erythroid lineage specific enhancer element.
10. The method of claim 3 , wherein:
post-transplantation fetal hemoglobin exceeds at least 20%;
F cells constitute at least ⅔ of the circulating red blood cells;
fetal hemoglobin per F cells account for at least ⅓ of total hemoglobin in sickle red blood cells; and
at least 20% gene-modified HSCs re-populate bone marrow of the subject.
11. A lentiviral expression vector capable of genetically correcting sickle cell anemia or β-thalassemia or reducing symptoms thereof, comprising the mutated human gamma-globin gene of claim 1 .
12. The lentiviral expression vector of claim 11 , further comprising:
a heterologous polyA signal sequence downstream from a viral 3′ LTR sequence in a standard SIN lentiviral vector backbone; and
one or more USE sequences derived from an SV40 late polyA signal in a U3 deletion region of a standard SIN lentiviral vector backbone.
13. The lentiviral expression vector of claim 12 , further comprising one or more flanking CHS4-derived reduced-length functional insulator sequences.
14. The lentiviral expression vector of claim 13 , further comprising one or more elements of a beta-globin locus control region cloned in reverse orientation to a viral transcriptional unit.
15. The lentiviral expression vector of claim 13 , further comprising an erythroid lineage specific enhancer element.